REG - MyCelx Tech. Corp. MyCelx Tech. Cp-MYXR - Broker Option

Canaccord GenuityAnnouncement

21/03/2022 19:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220321:nRSU5151Fa&default-theme=true

RNS Number : 5151F  MyCelx Technologies Corporation  21 March 2022

THIS ANNOUNCEMENT, (INCLUDING THE APPENDICES) AND THE TERMS AND CONDITIONS SET
OUT HEREIN (TOGETHER, THIS "ANNOUNCEMENT")  AND THE INFORMATION CONTAINED
THEREIN, IS RESTRICTED AND  IS NOT FOR PUBLICATION, RELEASE,  DISTRIBUTION
OR FORWARDING, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART,   TO ANY US
PERSONS OR IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE
REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION,
RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT
CONSTITUTE AN OFFER OF SECURITIES IN ANY JURISDICTION. PLEASE SEE THE
IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

 

21 March 2022

MYCELX Technologies Corporation

("MYCELX" or the "Company")

Broker Option

 

 

MYCELX Technologies Corporation (AIM: MYX), the clean water and clean air
technology company, is pleased to announce that further to the announcement of
the Proposed Placing and Subscription on 11 March 2022, the Broker Option has
been exercised in respect of 155,000 new Common Shares (the "Broker Option
Shares"), raising additional gross proceeds of $101,500 (c £77,500) for the
Company.

The Broker Option Shares will be issued at a price of 50 pence per new Common
Share (being the Issue Price) and on the same terms and conditions as the
Placing, including the fact that they are to be issued  into the new
restricted line of Common Shares under the symbol MYXR.

With the exercise of the Broker Option and the admission of the Placing and
Subscription to trading on AIM, this results in a total gross fundraise of
$2.31million (c.£1.77 million*) for the Company; comprising the Placing and
Subscription raising c.$2.21 million (c.£1.69 million*) (before expenses),
and the Broker Option raising $101,500 (c.£77,500*).

Admission and dealings

Application will be made to the London Stock Exchange for the 155,000 Broker
Option Shares to be admitted to trading on AIM (the "Further Admission").
Admission of the Placing and Subscription became effective on 21 March 2022,
the Broker Option Shares are expected to become effective and dealings
commence at 8.00 a.m. on or around 25 March 2022.

The new Common Shares to be issued in connection with the Placing and
Subscription and the Broker Option, when issued, rank pari passu with the
existing Common Shares, including the right to receive future dividends.

Upon the Further Admission, the new Common Shares issued pursuant to the
Broker Option will also trade in the Company's new restricted line of Common
Shares under the symbol MYXR, and the new Common Shares, as represented by
depositary interests ("Depository Interests"), will be held in the CREST
system and will be segregated into a separate trading system within CREST
identified with the marker "REG S" and USU624551235.

Total Voting Rights

Following the Further Admission, and as a result of the Broker Option being
partially exercised, the total number of Common Shares in the Company with
voting rights is expected to be 22,983,023.

Terms and definitions used in this announcement shall have the same meaning as
ascribed to them in the Company's announcements dated 11 March 2022 regarding
the Proposed Placing and Subscription unless otherwise stated.

 

*Exchange rate of GBP: USD 1.31

further information, please contact:

 MYCELX Technologies Corporation

 Connie Mixon, Chief Executive Officer                     +1 770 534 3118

 Kim Slayton, Chief Financial Officer

 Canaccord Genuity Limited (NOMAD, Broker and Bookrunner)
 Henry Fitzgerald-O'Connor                                 +44 207 523 8000

 Gordon Hamilton

 Sam Lucas (ECM)

 Celicourt Communications (Financial PR)

 Mark Antelme                                              +44 208 434 2643
 Jimmy Lea

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURUASBRUWUOUAR